MedTrace Logo

The South Proxa-Rescue AndroCoV Trial Against COVID-19

NCT05126628 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2021-11-19

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy of proxalutamide or hospitalized moderate-to-severe COVID-19 patients.

Conditions

Interventions

DRUG

Proxalutamide

Proxalutamide 300mg q.d.(3 tablets of 100mg each) for 14 days.

DRUG

Placebo

Placebo 3 tablets q.d. for 14 days

Sponsors & Collaborators

  • Hospital da Brigada Militar de Porto Alegre, Porto Alegre, Brazil

    collaborator UNKNOWN

  • Hospital Arcanjo Sao Miguel, Gramado, Brazil

    collaborator UNKNOWN

  • Hospital Unimed Chapeco, Chapeco, Brazil

    collaborator UNKNOWN

  • Corpometria Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-06
Primary Completion
2021-03-16
Completion
2021-04-15

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05126628 on ClinicalTrials.gov